Active, not recruitingPhase 2NCT05335993

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Studying Adenocarcinoma of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CanariaBio Inc.
Principal Investigator
Sunil Gupta, MD, FRCPC
CanariaBio Inc.
Intervention
Oregovomab(biological)
Enrollment
10 enrolled
Eligibility
18-99 years · FEMALE
Timeline
20222025

Study locations (3)

Collaborators

Veristat, LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05335993 on ClinicalTrials.gov

Other trials for Adenocarcinoma of ovary

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of ovary

← Back to all trials